KBTBD4 and neoplasm: Cluster 2 represents 60% (134/223) of all MBGroup3/4 tumours examined, indicating a wider involvement of KBTBD4 mutation-associated transcriptional programmes and CoREST pathways in this tumour group, with KBTBD4-mutated cases representing a subset (3/134) of these cases.